What smart money is saying about Charles River Laboratories International, Inc.
3 funds in our archive have pitched Charles River Laboratories International, Inc., most recently Ariel Mid Cap Value in December 2025.
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Get an email when a fund buys, sells or pitches it
Position history
Between Q4 2024 and Q3 2026, 19 fund letters reported a position in Charles River Laboratories International, Inc., with 2 buys (opened or added) and 3 sells (trimmed or exited).
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 8 | 0 | 1 | 0 |
| Q2 2026 | 7 | 0 | 1 | 0 |
| Q1 2026 | 1 | 0 | 0 | 0 |
| Q4 2025 | 0 | 0 | 0 | 1 |
| Q2 2025 | 1 | 1 | 0 | 1 |
| Q1 2025 | 1 | 0 | 1 | 0 |
| Q4 2024 | 1 | 1 | 0 | 1 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 19 positions · 5 moves
- September 2026
Listed in Oakmark Equity and Income Fund’s reported holdings.
Charles River Laboratories International, Inc. - September 2026
“Health care was the largest contributor to relative performance, with strength spanning across industry sectors. Natera, a leader in cell-free DNA testing, surged on a substantial beat-and-raise quarter led by record volumes for its cancer recurrence monitoring test, along with new regulatory directives that expand the test’s use. Charles River Laboratories, which was pressured earlier in the year on concerns that AI could reduce drug development spending, rebounded sharply as the company returned to organic growth for the first time in nearly three years, with bookings well ahead of expectations as biotech funding and biopharma spending show signs of recovery.”
Charles River Laboratories International, Inc. - September 2026
“Largest Contributors Charles River Laboratories International (CRL), the world’s largest provider of outsourced nonclinical drug development services, was the largest contributor. The company reported better than expected quarterly bookings and earnings, providing solid support for our thesis that demand is recovering after a period of cyclical contraction.”
Charles River Laboratories International, Inc. - September 2026
“Charles River Laboratories (CRL) advanced following a strong earnings report and an increase to full-year guidance.”
Charles River Laboratories International, Inc. - September 2026
“Selection within Health Care, a space that has been battered over the last several years outside of speculative areas like biotechnology, contributed most, with Charles River Laboratories, Integer Holdings, and CONMED signicantly outperforming benchmark constituents.”
Charles River Laboratories International, Inc. - September 2026
“Charles River Laboratories International (CRL), the world’s largest provider of outsourced nonclinical drug development services, was the largest contributor.”
Charles River Laboratories International, Inc. - September 2026
“Largest Contributors Charles River Laboratories International (CRL), the world’s largest provider of outsourced nonclinical drug development services, was the largest contributor.”
Charles River Laboratories International, Inc. - September 2026
“In addition, our Health Care positioning, with names such as Charles River Laboratories International, Inc. (CRL) which rose over +30%, was another standout contributor across all portfolios; however, the positive offset did not make up enough ground in the mid cap value portfolio.”
Charles River Laboratories International, Inc. - June 2026
“9 Generac Holdings, Inc. Industrials 3.11 10 Charles River Laboratories International, Inc. Health Care 3.02 Total 39.35”
Charles River Laboratories International, Inc. - June 2026
“SALES Charles River Laboratories (CRL) We sold Charles River Laboratories to fund our buy of Stevanato Group.”
Charles River Laboratories International, Inc. - June 2026
“Charles River Laboratories International (CRL), the world’s largest provider of outsourced nonclinical drug development services, was the second- largest contributor.”
Charles River Laboratories International, Inc. - June 2026
“RHP also announced late in the quarter that it is exploring a sale of its non-REIT Entertainment segment, potentially making the company a pure-play REIT and generating proceeds for further investment and capital returns. Charles River Laboratories International (CRL), the world’s largest provider of outsourced nonclinical drug development services, was the third-largest contributor.”
Charles River Laboratories International, Inc. - June 2026
“Charles River Laboratories International (CRL), the world’s largest provider of outsourced nonclinical drug development services, was the second- largest contributor.”
Charles River Laboratories International, Inc. - June 2026
“Largest Contributors MKS Inc. (MKSI), a supplier of critical subsystems and components used in semiconductor manufacturing and electronics packaging, was the largest contributor. Investors responded positively to increasing AI-related semiconductor demand. The stock also beneted from a better than expected rst quarter report which showed a meaningful increase in year-over-year revenue and above consensus earnings per share. Charles River Laboratories International (CRL), the world’s largest provider of outsourced nonclinical drug development services, was the second- largest contributor.”
Charles River Laboratories International, Inc. - June 2026
“Largest Contributors MKS Inc. (MKSI), a supplier of critical subsystems and components used in semiconductor manufacturing and electronics packaging, was the largest contributor. Investors responded positively to increasing AI-related semiconductor demand. The stock also beneted from a better than expected rst quarter report which showed a meaningful increase in year-over-year revenue and above consensus earnings per share. Charles River Laboratories International (CRL), the world’s largest provider of outsourced nonclinical drug development services, was the second-largest contributor.”
Charles River Laboratories International, Inc. - HoldsAriel Mid Cap ValueMarch 2026
“Shares of Charles River Laboratories (CRL) declined during the quarter as solid earnings results were overshadowed by a weaker than expected outlook.”
Charles River Laboratories International, Inc. - New positionHarris Oakmark Concentrated StrategyJune 2025
“PORTFOLIO POSITIONING We initiated the following position(s) during the pe- riod: • Charles River Labs is the world’s leading pro- vider of research models and other services for preclinical research and drug development.”
Charles River Laboratories International, Inc. - March 2025
“Charles River Laboratories, a provider of drug discovery services in the health care sector, was sold due to continued weakness among its large cap pharmaceutical customers as well as rhetoric from the Trump administration about cuts at the National Institutes of Health as well as volatile biotech funding trends.”
Charles River Laboratories International, Inc. - New positionUpslope Capital ManagementDecember 2024
“The Fund added three new disclosed longs: Charles River Labs (CRL), V.F. Corp (VFC), and QinetiQ (QQ.-LON).”
Charles River Laboratories International, Inc.
Also mentioned · 1
These funds discuss Charles River Laboratories International, Inc. as a competitor, benchmark or comparable, without disclosing a position in it.
- MentionedRhenman Healthcare Equity L/SOctober 2026
“During the month, research firm Citrini published a report with a parallel thesis for drug development, best summed up in the punchy quote “It’s harder to make monkeys than memory”. Their thesis is that AI will lead to more drug studies and thus to increased demand for monkeys for animal testing. Among others, Charles River, the world’s largest supplier of animal models, was highlighted as a result.”
Charles River Laboratories International, Inc.
Fund coverage · 3 theses
- Ariel Mid Cap ValueDecember 2025
Charles River Laboratories is a leading outsourced drug development provider with resilient demand, diversified growth in areas like cell and gene therapy, and pricing power supporting long-term growth.
Read the full thesis - Harris Oakmark Concentrated StrategyJune 2025
Charles River Labs is a leading provider of preclinical research services with a strong competitive advantage, poised for growth despite current challenges, making it an attractive investment opportunity.
Read the full thesis - Upslope Capital ManagementDecember 2024
Charles River’s strong market position and improving fundamentals suggest potential upside as the biotech cycle turns
Read the full thesis
Read every full thesis on Charles River Laboratories International, Inc.
Read all 3 theses in full, with each fund's reasoning, and get unlimited access to the archive.
View plans→